Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial

Munjireen Sifat, Emily T Hébert, Jasjit S Ahluwalia, Michael S Businelle, Joseph J C Waring, Summer G Frank-Pearce, Chase Bryer, Lizbeth Benson, Stefani Madison, Lourdes G Planas, Irina Baranskaya, Darla E Kendzor, Munjireen Sifat, Emily T Hébert, Jasjit S Ahluwalia, Michael S Businelle, Joseph J C Waring, Summer G Frank-Pearce, Chase Bryer, Lizbeth Benson, Stefani Madison, Lourdes G Planas, Irina Baranskaya, Darla E Kendzor

Abstract

Background: Varenicline and oral nicotine replacement therapy (NRT) have each been shown to increase the likelihood of smoking cessation, but their combination has not been studied. In addition, smoking cessation medication adherence is often poor, thus, challenging the ability to evaluate medication efficacy.

Objective: This study examined the effects of combined varenicline and oral NRT and smartphone medication reminders on pharmacotherapy adherence and smoking abstinence among adults enrolled in smoking cessation treatment.

Methods: A 2×2 factorial design was used. Participants (N=34) were randomized to (1) varenicline + oral NRT (VAR+NRT) or varenicline alone (VAR) and (2) smartphone medication reminder messages (REM) or no reminder messages (NREM) over 13 weeks. Participants assigned to VAR+REM received varenicline reminder prompts, and those assigned to VAR+NRT+REM also received reminders to use oral NRT. The other 2 groups (VAR+NREM and VAR+NRT+NREM) did not receive medication reminders. Participants were not blinded to intervention groups. All participants received tobacco cessation counseling. Smartphone assessments of smoking as well as varenicline and NRT use (if applicable) were prompted daily through the first 12 weeks after a scheduled quit date. Descriptive statistics were generated to characterize the relations between medication and reminder group assignments with daily smoking, daily varenicline adherence, and daily quantity of oral NRT used. Participants completed follow-up assessments for 26 weeks after the quit date.

Results: Participants were predominantly White (71%), and half were female (50%). On average, participants were 54.2 (SD 9.4) years of age, they smoked an average of 19.0 (SD 9.0) cigarettes per day and had smoked for 34.6 (SD 12.7) years. Descriptively, participants assigned to VAR+NRT reported more days of smoking abstinence compared to VAR (29.3 vs 26.3 days). Participants assigned to REM reported more days of smoking abstinence than those assigned to NREM (40.5 vs 21.8 days). Participants assigned to REM were adherent to varenicline on more days compared to those assigned to NREM (58.6 vs 40.5 days), and participants assigned to VAR were adherent to varenicline on more days than those assigned to VAR + NRT (50.7 vs 43.3 days). In the subsample of participants assigned to VAR+NRT, participants assigned to REM reported more days where ≥5 pieces of NRT were used than NREM (14.0 vs 7.4 days). Average overall medication adherence (assessed via the Medication Adherence Questionnaire) showed the same pattern as the daily smartphone-based adherence assessments.

Conclusions: Preliminary findings indicated that smoking cessation interventions may benefit from incorporating medication reminders and combining varenicline with oral NRT, though combining medications may be associated with poorer adherence. Further study is warranted.

Trial registration: ClinicalTrials.gov NCT03722966; https://classic.clinicaltrials.gov/ct2/show/NCT03722966.

Keywords: NRT; cessation; controlled trial; mHealth; medication adherence; mobile phone; nicotine; nicotine replacement therapy; quit; quitting; randomized; smartphone-based medication reminders; smoke; smoker; smoking; smoking cessation; varenicline combined with oral nicotine replacement therapy.

Conflict of interest statement

Conflicts of Interest: MSB and DEK are inventors of the Insight mHealth Platform, which was used to develop the study app. They receive royalties related to its use. However, they did not receive royalties in this case. JSA received sponsored funds for travel expenses as a speaker for the 2021 and 2022 annual GTNF conference. JSA serves as a consultant, receives compensation, and has equity in Qnovia, a start-up company developing a prescription nicotine replacement product for FDA approval.

©Munjireen Sifat, Emily T Hébert, Jasjit S Ahluwalia, Michael S Businelle, Joseph J C Waring, Summer G Frank-Pearce, Chase Bryer, Lizbeth Benson, Stefani Madison, Lourdes G Planas, Irina Baranskaya, Darla E Kendzor. Originally published in JMIR Formative Research (https://formative.jmir.org), 27.10.2023.

References

    1. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54. doi: 10.3322/caac.21440.
    1. Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults: United States, 2020. MMWR Morb Mortal Wkly Rep. 2022;71(11):397–405. doi: 10.15585/mmwr.mm7111a1. doi: 10.15585/mmwr.mm7111a1.
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
    1. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–350. doi: 10.1056/NEJMsa1211128.
    1. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froehlicher ES, Goldstein MG, Healton C, Henderson PN, Heyman RB, Koh HK, Kottke TE, Lando HA, Mecklenburg RE, Mermelstein R, Mullen PD, Orleans CT, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services; 2008. [2023-04-01].
    1. Hughes JR. An updated algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2013;45(2):215–221. doi: 10.1016/j.jsat.2013.01.011. S0740-5472(13)00034-2
    1. Jordan CJ, Xi ZX. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;13(7):671–683. doi: 10.1080/17460441.2018.1458090.
    1. Love BL. Varenicline (Chantix) for smoking cessation. Am Fam Physician. 2007;76(2):279–280.
    1. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016;11(6):4–7. doi: 10.1176/appi.ajp-rj.2016.110602.
    1. King A, Vena A, de Wit H, Grant JE, Cao D. Effect of combination treatment with varenicline and nicotine patch on smoking cessation among smokers who drink heavily: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e220951. doi: 10.1001/jamanetworkopen.2022.0951. 2789620
    1. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014;12:172. doi: 10.1186/s12916-014-0172-8. s12916-014-0172-8
    1. Koegelenberg CFN, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312(2):155–161. doi: 10.1001/jama.2014.7195. 1886188
    1. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med. 2013;11:140. doi: 10.1186/1741-7015-11-140. 1741-7015-11-140
    1. Baker TB, Piper ME, Smith SS, Bolt DM, Stein JH, Fiore MC. Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial. JAMA. 2021;326(15):1485–1493. doi: 10.1001/jama.2021.15333. 2785264
    1. Musa R, Haddad I, Thomas A, Karakattu S, El Abbassi A. Combined nicotine replacement therapy (nicotine patch) and varenicline vs varenicline alone for smoking cessation: a systematic review and meta-analysis. Chest. 2021;160(4):A2458. doi: 10.1016/j.chest.2021.07.2124.
    1. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15:689. doi: 10.1186/s12889-015-2055-0. 10.1186/s12889-015-2055-0
    1. Nides M, Shanga GM, Bishop A, Becker WD. Nicotine lozenges in the relief of behaviorally provoked craving. Am J Health Behav. 2018;42(3):69–80. doi: 10.5993/AJHB.42.3.7.
    1. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007;9(9):947–954. doi: 10.1080/14622200701540820. 781694091
    1. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, Petkova E, Rodriguez K. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102(8):1292–1302. doi: 10.1111/j.1360-0443.2007.01887.x.ADD1887
    1. Mobile fact sheet. Pew Research Center. 2021. [2021-04-07].
    1. Bruno M, Wright M, Baker CL, Emir B, Carda E, Clausen M, Sigler C, Patel A. Mobile app usage patterns of patients prescribed a smoking cessation medicine: prospective observational study. JMIR Mhealth Uhealth. 2018;6(4):e97. doi: 10.2196/mhealth.9115. v6i4e97
    1. McClure JB, Anderson ML, Bradley K, An LC, Catz SL. Evaluating an adaptive and interactive mHealth smoking cessation and medication adherence program: a randomized pilot feasibility study. JMIR Mhealth Uhealth. 2016;4(3):e94. doi: 10.2196/mhealth.6002. v4i3e94
    1. Rathbone AL, Prescott J. The use of mobile apps and SMS messaging as physical and mental health interventions: systematic review. J Med Internet Res. 2017;19(8):e295. doi: 10.2196/jmir.7740. v19i8e295
    1. Raupach T, Brown J, Herbec A, Brose L, West R. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction. 2014;109(1):35–43. doi: 10.1111/add.12319.
    1. Hébert ET, Bhushan T, Ra CK, Frank-Pearce S, Alexander AC, Cole AB, Kendzor DE, Businelle MS. Daily use of nicotine replacement medications is related to daily smoking status: an ecological momentary assessment study. Drug Alcohol Depend. 2021;229(Pt A):109161. doi: 10.1016/j.drugalcdep.2021.109161. S0376-8716(21)00656-6
    1. Ma P, Kendzor DE, Poonawalla IB, Balis DS, Businelle MS. Daily nicotine patch wear time predicts smoking abstinence in socioeconomically disadvantaged adults: an analysis of ecological momentary assessment data. Drug Alcohol Depend. 2016;169:64–67. doi: 10.1016/j.drugalcdep.2016.10.013.S0376-8716(16)30948-6
    1. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, Tyndale RF, Okuyemi KS, Ahluwalia JS. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst. 2012;104(4):290–298. doi: 10.1093/jnci/djr513. djr513
    1. Pacek LR, McClernon FJ, Bosworth HB. Adherence to pharmacological smoking cessation interventions: a literature review and synthesis of correlates and barriers. Nicotine Tob Res. 2018;20(10):1163–1172. doi: 10.1093/ntr/ntx210. 4159986
    1. Al-Arkee S, Mason J, Lane DA, Fabritz L, Chua W, Haque MS, Jalal Z. Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis. J Med Internet Res. 2021;23(5):e24190. doi: 10.2196/24190. v23i5e24190
    1. Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, Graham G, Marvel FA, Martin SS. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes. 2016;2(4):237–244. doi: 10.1093/ehjqcco/qcw018. 2236146
    1. Xu H, Long H. The effect of smartphone app-based interventions for patients with hypertension: systematic review and meta-analysis. JMIR Mhealth Uhealth. 2020;8(10):e21759. doi: 10.2196/21759. v8i10e21759
    1. Cobos-Campos R, de Lafuente AS, Apiñaniz A, Parraza N, Llanos IP, Orive G. Effectiveness of mobile applications to quit smoking: systematic review and meta-analysis. Tob Prev Cessat. 2020;6:62. doi: 10.18332/tpc/127770. 62
    1. Tobacco Treatment Research Program (TTRP) TSET Health Promotion Research Center. 2023. [2023-08-16]. .
    1. Arozullah AM, Yarnold PR, Bennett CL, Soltysik RC, Wolf MS, Ferreira RM, Lee SYD, Costello S, Shakir A, Denwood C, Bryant FB, Davis T. Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care. 2007;45(11):1026–1033. doi: 10.1097/MLR.0b013e3180616c1b.00005650-200711000-00004
    1. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, Joseph A, Oncken C, Piper ME. Biochemical verification of tobacco use and abstinence: 2019 update. Nicotine Tob Res. 2020;22(7):1086–1097. doi: 10.1093/ntr/ntz132. 5579733
    1. Roaldset JO, Linaker OM, Bjørkly S. Predictive validity of the MINI suicidal scale for self-harm in acute psychiatry: a prospective study of the first year after discharge. Arch Suicide Res. 2012;16(4):287–302. doi: 10.1080/13811118.2013.722052.
    1. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103–115.
    1. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials: a review. Control Clin Trials. 2002;23(6):662–674. doi: 10.1016/s0197-2456(02)00242-8.S0197245602002428
    1. Pfizer expands voluntary nationwide recall to include all lots of CHANTIX® (varenicline) tablets due to N-nitroso varenicline content. U.S. Food and Drug Administration. 2021. [2022-11-05]. .
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208. S1532-0464(19)30126-1
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010. S1532-0464(08)00122-6
    1. Mobile health technology: Insight platform. TSET Health Promotion Research Center. 2022. [2023-08-16]. .
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. doi: 10.1097/00005650-198601000-00007.
    1. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4(4):CD013308. doi: 10.1002/14651858.CD013308.
    1. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs. 2010;70(6):643–650. doi: 10.2165/11536100-000000000-00000. 1
    1. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145(11):845–856. doi: 10.7326/0003-4819-145-11-200612050-00142. 0000605-200612050-00142
    1. Loh WY, Piper ME, Schlam TR, Fiore MC, Smith SS, Jorenby DE, Cook JW, Bolt DM, Baker TB. Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine Tob Res. 2012;14(2):131–141. doi: 10.1093/ntr/ntr147. ntr147
    1. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4.
    1. Mersha AG, Eftekhari P, Bovill M, Tollosa DN, Gould GS. Evaluating level of adherence to nicotine replacement therapy and its impact on smoking cessation: a systematic review and meta-analysis. Arch Public Health. 2021;79(1):26. doi: 10.1186/s13690-021-00550-2. 10.1186/s13690-021-00550-2
    1. Kelly M, McCarthy S, Sahm LJ. Knowledge, attitudes and beliefs of patients and carers regarding medication adherence: a review of qualitative literature. Eur J Clin Pharmacol. 2014;70(12):1423–1431. doi: 10.1007/s00228-014-1761-3.
    1. Hébert ET, Ra CK, Alexander AC, Helt A, Moisiuc R, Kendzor DE, Vidrine DJ, Funk-Lawler RK, Businelle MS. A mobile just-in-time adaptive intervention for smoking cessation: pilot randomized controlled trial. J Med Internet Res. 2020;22(3):e16907. doi: 10.2196/16907. v22i3e16907

Source: PubMed

3
Suscribir